



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jing Zhu et al.

Title: USE OF PROEPITHELIN TO PROMOTE WOUND REPAIR AND REDUCE  
INFLAMMATION

Docket No.: 1676.011US1  
Filed: December 12, 2003  
Examiner: Fozia M. Hamud

Serial No.: 10/735,289  
Due Date: October 6, 2006  
Group Art Unit: 1647

**MS Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ Return postcard.  
☒ Response to Restriction Requirement (10 pgs.).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
Customer Number 21186

By: Robin A. Chadwick  
Atty: Robin A. Chadwick  
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 06 day of October, 2006.

Dawn M. Poole  
Name

Dawn M. Poole  
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
(GENERAL)



10/N 10/735,289

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	JING ZHU ET AL.	Examiner:	Fozia M. Hamud
Serial No.:	10/735,289	Group Art Unit:	1647
Filed:	December 12, 2003	Docket:	1676.011US1
Title:	USE OF PROEPITHELIN TO PROMOTE WOUND REPAIR AND REDUCE INFLAMMATION		

---

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In response to the Restriction Requirement mailed September 6, 2006, Applicant elects, with traverse, the subject matter of Group I (claims 1-46), drawn, in part, to a method of administering to a mammal a proepithelin (PEPI), alone or with secretory leukocyte protease inhibitor (SLPI), wherein said PEP1 comprises the amino acid sequence SEQ ID NO:1 and the SLPI comprises the amino acid sequence set forth in SEQ ID NO:7.

Applicant further requests that the Examiner search and examine Group II (claims 1-46) because the only difference between the subject matter of Groups I and II is that the PEPI has SEQ ID NO:2 in Group II, which is identical to the SEQ ID NO:1 in Group I except for a single amino acid difference at position 454 (Gly in SEQ ID NO:1; Gln in SEQ ID NO:2).

Accordingly, search and examination of Group II with Group I would not be overly burdensome compared to a search and examination of Group I alone.